Goldman Sachs Group Inc Myovant Sciences Ltd. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	BUY	$24.03 - $27.02 $46.4 Million - $52.1 Million	1,929,497 Added 392.84%	2,420,659 $65.3 Million
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $46.4 Million - $52.1 Million	1,929,497 Added 392.84%	2,420,659 $65.3 Million
Q3 2022 May 14, 2024	BUY	$11.6 - $20.44 $844,781 - $1.49 Million	72,826 Added 17.41%	491,162 $8.82 Million
Q3 2022 Nov 10, 2022	BUY	$11.6 - $20.44 $844,781 - $1.49 Million	72,826 Added 17.41%	491,162 $8.82 Million
Q2 2022 May 14, 2024	BUY	$7.78 - $14.69 $3.25 Million - $6.15 Million	418,336 New	418,336 $5.2 Million
Q2 2022 Aug 15, 2022	BUY	$7.78 - $14.69 $1.62 Million - $3.05 Million	207,827 Added 98.73%	418,336 $5.2 Million
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $239,196 - $344,711	21,019 Added 11.09%	210,509 $2.8 Million
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $863,451 - $1.44 Million	60,339 Added 46.72%	189,490 $2.95 Million
Q3 2021 Nov 10, 2021	BUY	$18.94 - $26.99 $2.45 Million - $3.49 Million	129,151 New	129,151 $2.9 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.